Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment

Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice

(2016) William D. Leslie et al.   ANNALS OF INTERNAL MEDICINE

Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis

(2016) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Clinical Implications of Hip Flexion in the Measurement of Spinal Bone Mineral Density

(2016) Shota Ikegami et al.   JOURNAL OF CLINICAL DENSITOMETRY

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients

(2016) M. Kamimura et al.   OSTEOPOROSIS INTERNATIONAL

The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations

(2015) Shigeharu Uchiyama et al.   BONE

Parathyroid hormone: anabolic and catabolic actions on the skeleton

(2015) Barbara C Silva et al.   CURRENT OPINION IN PHARMACOLOGY

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

(2015) Jean-Jacques Body et al.   EUROPEAN JOURNAL OF CANCER

Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) T. Sugimoto et al.   OSTEOPOROSIS INTERNATIONAL

Identification of the Risk Factors Associated with Hypocalcemia Induced by Denosumab

(2013) Naoto Okada et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis

(2013) Christian Roux et al.   CALCIFIED TISSUE INTERNATIONAL

Denosumab in osteoporosis

(2013) Dima L Diab et al.   Expert Opinion On Drug Safety

25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis

(2012) Pilar Peris et al.   BONE

Effects of 25-Hydroxyvitamin D3Therapy on Bone Turnover Markers and PTH Levels in Postmenopausal Osteoporotic Women Treated with Alendronate

(2012) José M. Olmos et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The impact of dietary calcium intake and vitamin D status on the effects of zoledronate

(2012) S. Bourke et al.   OSTEOPOROSIS INTERNATIONAL

Vitamin D insufficiency does not affect response of bone mineral density to alendronate

(2008) D. M. Antoniucci et al.   OSTEOPOROSIS INTERNATIONAL